Sartorius Stedim Biotech (SDMHF) Projected to Post Earnings on Thursday

Sartorius Stedim Biotech (OTCMKTS:SDMHF) is projected to release its resultson Thursday, April 23rd. Analysts expect Sartorius Stedim Biotech to post earnings of $1.23 per share and revenue of $755.0090 million for the quarter.

Sartorius Stedim Biotech Price Performance

Shares of OTCMKTS:SDMHF opened at $218.06 on Tuesday. The company’s 50-day moving average price is $202.19 and its two-hundred day moving average price is $224.41. Sartorius Stedim Biotech has a one year low of $178.30 and a one year high of $264.30.

Analysts Set New Price Targets

Several brokerages have commented on SDMHF. Barclays reissued an “overweight” rating on shares of Sartorius Stedim Biotech in a research report on Tuesday, January 6th. The Goldman Sachs Group cut shares of Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a research report on Monday, January 12th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Sartorius Stedim Biotech presently has an average rating of “Hold”.

Sartorius Stedim Biotech Company Profile

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.